JPET Data Acquisition and Analysis Systems for the Life Sciences

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 21, 2005; DOI: 10.1124/jpet.105.086504


0022-3565/05/3142-626-635$20.00
JPET 314:626-635, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.086504v1
314/2/626    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leeder, J. S.
Right arrow Articles by Pearce, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leeder, J. S.
Right arrow Articles by Pearce, R. E.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Variability of CYP3A7 Expression in Human Fetal Liver

J. Steven Leeder, Roger Gaedigk, Kenda A. Marcucci, Andrea Gaedigk, Carrie A. Vyhlidal, Bradley P. Schindel, and Robin E. Pearce

Section of Developmental Pharmacology and Experimental Therapeutics, Division of Pediatric Pharmacology and Medical Toxicology, Department of Pediatrics, Children's Mercy Hospital and Clinics, Kansas City, Missouri

Fetal liver CYP3A7 plays an important role in placental estriol synthesis during pregnancy, yet little is known concerning the extent or consequences of variability in expression. The purpose of this investigation was to characterize the variability in CYP3A7 expression using several phenotypic measures in a panel of 54 fetal livers ranging in age from 76 days to 32 weeks gestation. CYP3A7 mRNA expression was measured using quantitative polymerase chain reaction, whereas immunoreactive CYP3A7 was determined using an affinity-purified antipeptide antibody. Variability in catalytic activity was evaluated using testosterone and dehydroepiandrosterone (DHEA) as substrates. Across the entire panel, CYP3A7 was the most abundant CYP3A mRNA species present and varied 634-fold from 151 to 95,700 transcripts/ng total RNA, corrected for 18S ribosomal RNA. CYP3A4 expression was minimal based on mRNA expression (1000-fold lower than CYP3A7) and the ratio of testosterone 2{alpha}- (T2{alpha}H) to 6{beta}- (T6{beta}H) hydroxylation. T2{alpha}H and T6{beta}H were highly correlated (r2 = 0.859), and the correlation increased (r2 = 0.974) in livers with CYP3A5*3/*3 genotypes implying that the same enzyme (CYP3A7) generated both products. Overall, T2{alpha}H and DHEA16{alpha}H activities varied 175- and 250-fold, respectively. A subset of five samples had extremely low mRNA, protein, and catalytic activity, possibly due to pathology affecting fetal viability (anencephaly, porencephaly). In the remaining samples, T2{alpha}H activity varied 6.7-fold (358 ± 142, range 97 to 643 pmol/min/mg) and DHEA16{alpha}H activity varied 6.2-fold (8.07 ± 2.87, range 2.41 to 14.9 nmol/min/mg). Observed variability in CYP3A7 activity was not related to CYP3A7*2, and alternative regulatory mechanisms require further investigation.


Received March 17, 2005; accepted April 18, 2005.

Address correspondence to: Dr. J. Steven Leeder, Section of Developmental Pharmacology and Experimental Therapeutics, Children's Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108. E-mail: sleeder{at}cmh.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. Gaedigk, D. W. Baker, R. A. Totah, R. Gaedigk, R. E. Pearce, C. A. Vyhlidal, D. C. Zeldin, and J. S. Leeder
Variability of CYP2J2 Expression in Human Fetal Tissues
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 523 - 532.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
R. E. Pearce, J. S. Leeder, and G. L. Kearns
BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATION
Drug Metab. Dispos., June 1, 2006; 34(6): 1035 - 1040.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
C. A. Vyhlidal, R. Gaedigk, and J. S. Leeder
NUCLEAR RECEPTOR EXPRESSION IN FETAL AND PEDIATRIC LIVER: CORRELATION WITH CYP3A EXPRESSION
Drug Metab. Dispos., January 1, 2006; 34(1): 131 - 137.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.